Free tool
FAERS Monitor: Invokana
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204042 or its brand name (Invokana, Canagliflozin). Reports on generic versions are filed under their own applications.
Reports
29,868
Serious
19,370
65% of reports
Hospitalization
10,749
Death reported
700
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diabetic ketoacidosis3,441
- toe amputation2,196
- osteomyelitis2,165
- acute kidney injury2,008
- fungal infection1,447
- weight decreased1,349
- blood glucose increased1,235
- gangrene1,086
- cellulitis1,036
- nausea1,026
- off label use1,021
- urinary tract infection1,019
- drug ineffective1,016
- dizziness847
- diabetic foot infection834
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 246 |
| 2014 | 984 |
| 2015 | 7,889 |
| 2016 | 4,292 |
| 2017 | 4,362 |
| 2018 | 4,643 |
| 2019 | 2,386 |
| 2020 | 1,465 |
| 2021 | 824 |
| 2022 | 811 |
| 2023 | 690 |
| 2024 | 502 |
| 2025 | 477 |
| 2026 | 291 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,024,291 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diabetic foot infectionSignal | 834 | 1007.0 | 906.4 | 344,446 |
| toe amputationSignal | 2,196 | 535.4 | 507.1 | 665,185 |
| gangreneSignal | 1,086 | 154.6 | 144.9 | 135,768 |
| diabetic ketoacidosisSignal | 3,441 | 117.6 | 113.6 | 341,057 |
| osteomyelitisSignal | 2,165 | 95.5 | 91.5 | 178,382 |
| fungal infectionSignal | 1,447 | 31.9 | 30.3 | 41,488 |
| cellulitisSignal | 1,036 | 14.8 | 13.9 | 13,035 |
| acute kidney injurySignal | 2,008 | 9.3 | 9.0 | 14,876 |
| blood glucose increasedSignal | 1,235 | 4.6 | 4.4 | 3,531 |
| urinary tract infectionSignal | 1,019 | 4.2 | 4.0 | 2,512 |
| weight decreasedSignal | 1,349 | 3.4 | 3.2 | 2,321 |
| dizziness | 847 | 1.2 | 1.1 | 28 |
| nausea | 1,026 | 0.9 | 0.9 | 9 |
| off label use | 1,021 | 0.8 | 0.8 | 41 |
| drug ineffective | 1,016 | 0.5 | 0.5 | 417 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.